MedTrace Logo

New AI-based Technologies in Nuclear Medicine

NCT07174089 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2025-09-15

No results posted yet for this study

Summary

The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring. It also investigates the correlation between extravasation and SUV correction in PET/CT diagnostics, providing an estimate of the correction factor necessary for accurate SUV evaluation in case of an extravasation event.

Conditions

  • Patients Undergoing PET/CT Investigation or Nuclear Medicine Therapy

Interventions

OTHER

RadEye SPRD-ER device: spectrometric radiation detector capable of detecting gamma radiation.

Acquisition of data during the infusion of PET radiotracers and the administration of α and β emitting radiopharmaceuticals for therapy.

Sponsors & Collaborators

  • Azienda USL Reggio Emilia - IRCCS

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-30
Primary Completion
2022-09-30
Completion
2026-03-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07174089 on ClinicalTrials.gov